Ortoma AB
Ortoma AB is a Swedish company that develops and commercializes medical devices, primarily focused on orthopedic and sports medicine solutions, generating revenue through product sales and licensing agreements.
Business. Ortoma AB (ORTB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Ortoma AB (ORTB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Ortoma AB operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0. The company's liquidity position is characterized by a current ratio of 3.12, indicating a strong short-term liquidity buffer relative to its current liabilities. However, the company's operating cash flow is negative at -6,364,870 SEK, and free cash flow is also negative at -6,540,980 SEK, suggesting that the company is not generating sufficient cash from operations to sustain its activities without external financing.
Profitability metrics are negative across the board. The company reported a net loss of -5,600,160 SEK, with a return on equity of -3.33% and a return on assets of -3.04%. These figures are significantly below the industry median for profitability metrics, indicating that Ortoma is underperforming relative to its peers in the Advanced Medical Equipment & Technology industry.
Geographically and segment-wise, the company's revenue is not disclosed by region or product line in the available data. However, the absence of segmental breakdowns suggests that Ortoma may be concentrated in a single geographic market or product offering, which could expose it to higher concentration risk. The company's growth trajectory is also unclear, as the available data does not provide a multi-year revenue history or forward-looking guidance.
The company's risk profile is marked by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the negative operating and free cash flows suggest a potential need for future financing, which could lead to dilution if the company issues additional shares. The absence of long-term debt is a positive factor, but the company's reliance on equity financing could increase its cost of capital over time.
Recent events and filings do not provide specific details on Ortoma's strategic initiatives or operational changes. Analyst estimates suggest that the company is expected to continue reporting losses, with a mean EPS estimate of -1.02 SEK and a mean EBIT estimate of -39,000,000 SEK. These estimates indicate that the company is not expected to achieve profitability in the near term, and its revenue is projected to remain below analyst expectations.
- Ortoma AB is currently operating at a net loss with negative cash flows from operations and free cash flow.
- The company is entirely equity-funded, with no long-term debt, but its liquidity position is strong due to a high current ratio.
- Profitability metrics are significantly below industry medians, indicating underperformance relative to peers.
- The company's geographic and segmental exposure is not disclosed, suggesting potential concentration risk.
- Analysts expect continued losses, with no indication of near-term profitability or revenue growth.
Bull / Bear case
Generated · model-assistedOrtoma AB maintains zero long-term debt, providing a debt-to-equity ratio of 0.0 that exceeds the cohort median of 0.11.
The company's cash conversion metric of 1.14 ranks above the cohort median of 0.82, indicating superior operational efficiency.
Revenue growth trajectory shows an increase from 38.1 million SEK in FY2024 to 64.6 million SEK in FY2026.
Dilution and liquidity risks are assessed as low, suggesting stable capital structure and market access conditions.
Operating margin of -1.28 is significantly below the cohort median of -0.14, indicating severe profitability challenges relative to peers.
The company carries a high credit risk flag, signaling potential difficulties in meeting financial obligations or securing financing.
Net margin of -1.26 falls well below the cohort median of -0.16, reflecting persistent inability to generate net income.
Capex to revenue ratio of -0.90 places the company in the bottom quartile, suggesting inefficient capital deployment.
In focus — financials by report
Revenue kr 4.7M, −72,7% YoY; Operating income −103,1% YoY.
- ▍Revenue kr 4.7M, −72,7% YoY
- ▍Operating income −103,1% YoY
- ▍Net income −111,0% YoY
- ▍Free cash flow −125,4% YoY
- ▍Net margin -471.5%
Revenue kr 2.4M, −75,5% YoY; Operating income −1 134,7% YoY.
- ▍Revenue kr 2.4M, −75,5% YoY
- ▍Operating income −1 134,7% YoY
- ▍Net income −1 463,3% YoY
- ▍Free cash flow −4 682,2% YoY
- ▍Net margin -600.5%
Revenue kr 18.8M, +7,3% YoY; Operating income −75,3% YoY.
- ▍Revenue kr 18.8M, +7,3% YoY
- ▍Operating income −75,3% YoY
- ▍Net income −76,8% YoY
- ▍Free cash flow −6,2% YoY
- ▍Net margin 6.7%
Revenue kr 38.7M, +772,0% YoY; Operating income +387,3% YoY.
- ▍Revenue kr 38.7M, +772,0% YoY
- ▍Operating income +387,3% YoY
- ▍Net income +391,1% YoY
- ▍Free cash flow +372,7% YoY
- ▍Net margin 42.1%
Revenue kr 17.3M; Operating income -kr 11.1M.
- ▍Revenue kr 17.3M
- ▍Operating income -kr 11.1M
- ▍Net margin -61.0%
Revenue kr 9.9M; Operating income -kr 1.2M.
- ▍Revenue kr 9.9M
- ▍Operating income -kr 1.2M
- ▍Net margin -9.4%
Revenue kr 17.5M; Operating income kr 5.1M.
- ▍Revenue kr 17.5M
- ▍Operating income kr 5.1M
- ▍Net margin 30.9%
Revenue kr 4.4M; Operating income -kr 5.7M.
- ▍Revenue kr 4.4M
- ▍Operating income -kr 5.7M
- ▍Net margin -126.1%
Revenue kr 64.6M, +31,6% YoY; Operating income −52,2% YoY.
- ▍Revenue kr 64.6M, +31,6% YoY
- ▍Operating income −52,2% YoY
- ▍Net income −65,0% YoY
- ▍Free cash flow +14,9% YoY
- ▍Net margin -29.7%
Revenue kr 49.1M, +28,8% YoY; Operating income +41,6% YoY.
- ▍Revenue kr 49.1M, +28,8% YoY
- ▍Operating income +41,6% YoY
- ▍Net income +46,8% YoY
- ▍Free cash flow +72,2% YoY
- ▍Net margin -23.7%
Revenue kr 38.1M; Operating income −46,7% YoY.
- ▍Revenue kr 38.1M
- ▍Operating income −46,7% YoY
- ▍Net income −38,9% YoY
- ▍Free cash flow −1,5% YoY
- ▍Net margin -57.3%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,02 |
| Revenue | —no estimate | —no estimate | 73,0M SEK |
| Operating income | —no estimate | —no estimate | -39,0M SEK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Ortoma AB Market data — financials · 2026-05-28
- Ortoma AB Market data — analyst estimates · 2026-05-28